AR025103A1 - Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos - Google Patents

Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos

Info

Publication number
AR025103A1
AR025103A1 ARP000104148A ARP000104148A AR025103A1 AR 025103 A1 AR025103 A1 AR 025103A1 AR P000104148 A ARP000104148 A AR P000104148A AR P000104148 A ARP000104148 A AR P000104148A AR 025103 A1 AR025103 A1 AR 025103A1
Authority
AR
Argentina
Prior art keywords
reversion
pharmacos
neuromuscular block
chemical chemicals
block induced
Prior art date
Application number
ARP000104148A
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR025103A1 publication Critical patent/AR025103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere al uso de quelantes químicos para la preparacion de un medicamento para la reversion del bloqueo neuromuscular inducidopor fármacos, a un kit para proporcionar bloqueo neuromuscular y su reversion, y a derivados de ciclofano que tienen la formula general (1):en donde R es (CH2)5 o formula (2) o (3); o la formula general (4) donde X es (CH2)5 o formula (2) o (5) o sus sales farmacéuticamente aceptables.
ARP000104148A 1999-08-13 2000-08-11 Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos AR025103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99306411 1999-08-13

Publications (1)

Publication Number Publication Date
AR025103A1 true AR025103A1 (es) 2002-11-06

Family

ID=8241574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104148A AR025103A1 (es) 1999-08-13 2000-08-11 Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos

Country Status (11)

Country Link
US (3) US7265099B1 (es)
EP (1) EP1210090B1 (es)
JP (1) JP4782334B2 (es)
CN (1) CN1241576C (es)
AR (1) AR025103A1 (es)
AU (1) AU780416B2 (es)
BR (1) BR0013126A (es)
CA (1) CA2380920C (es)
IL (1) IL147887A0 (es)
MX (1) MXPA02001545A (es)
WO (1) WO2001012202A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2003077906A1 (en) * 2002-03-18 2003-09-25 Nihon University Cyclic etheramine derivatives as medicaments for malignant tumors
EP2125742A2 (en) * 2007-03-08 2009-12-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
CA2681060A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
US8357807B2 (en) * 2007-05-01 2013-01-22 Chemagis Ltd. Isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates
WO2008132748A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
AU2008264802A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
EP2176227A1 (en) * 2007-07-09 2010-04-21 Chemagis Ltd. Process for producing cisatracurium and associated intermediates
BRPI0816519A2 (pt) * 2007-10-29 2015-03-24 Chemagis Ltd Processo para preparar um sal de r, r'-atracúrio isomericamente enriquecido e sal de r, r'-atracúrio
WO2009133556A2 (en) * 2008-05-01 2009-11-05 Chemagis Ltd. Cisatracurium derivatives, preparation and uses thereof
CA2738018A1 (en) * 2008-09-22 2010-03-25 Arcarios B.V. Carboxyethylated cyclodextrin polysulfates useful as medicaments
US11013750B2 (en) 2017-01-20 2021-05-25 Aurin Biotech Inc. Methods for treating and preventing nociceptive pain
EP3830184A1 (en) 2018-08-02 2021-06-09 Pliva Hrvatska D.O.O. Solid state forms of sugammadex sodium
US11324692B2 (en) 2019-07-03 2022-05-10 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions of suggamadex
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex
ES2949710T1 (es) 2020-07-03 2023-10-02 Galenicum Health S L U Método para preparar composiciones farmacéuticas
CN113387798B (zh) * 2021-05-08 2022-10-11 上海大学 用作逆转神经肌肉阻滞剂的水溶性柱[n]芳烃及其应用
CN113509486B (zh) * 2021-06-16 2022-07-19 南开沧州渤海新区绿色化工研究有限公司 Cca-cd共组装体在制备大分子毒素解毒药物中的应用
CN115057797B (zh) * 2022-02-24 2023-06-23 上海大学 一种水溶性联苯芳烃的合成及生物毒素解毒的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
ES2067854T3 (es) 1990-03-15 1995-04-01 Tanabe Seiyaku Co Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo.
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5767112A (en) 1994-10-21 1998-06-16 Poli Industria Chimica, S.P.A. Muscle relaxant pharmaceutical compositions
AU708107B2 (en) * 1994-11-04 1999-07-29 Commonwealth Scientific And Industrial Research Organisation Method for treating animals
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
JP4249282B2 (ja) 1998-02-27 2009-04-02 日本食品化工株式会社 新規シクロデキストリン誘導体及びその製造方法

Also Published As

Publication number Publication date
BR0013126A (pt) 2002-04-23
CN1370073A (zh) 2002-09-18
CA2380920C (en) 2011-07-19
US20070299035A1 (en) 2007-12-27
EP1210090A2 (en) 2002-06-05
WO2001012202A2 (en) 2001-02-22
JP2003507335A (ja) 2003-02-25
CA2380920A1 (en) 2001-02-22
WO2001012202A3 (en) 2001-11-15
US7265099B1 (en) 2007-09-04
EP1210090B1 (en) 2014-06-18
CN1241576C (zh) 2006-02-15
AU780416B2 (en) 2005-03-17
IL147887A0 (en) 2002-08-14
MXPA02001545A (es) 2002-08-30
US20100075938A1 (en) 2010-03-25
AU7508900A (en) 2001-03-13
JP4782334B2 (ja) 2011-09-28

Similar Documents

Publication Publication Date Title
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
ATE297910T1 (de) Retinoid x rezeptormodulatoren
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
ATE297203T1 (de) Antithrombotische mitteln
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
ATE332903T1 (de) Kondensierte pyridoindolderivate
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
BRPI0111142C1 (pt) utilização de derivados de biguanida ou sais farmaceuticamente aceitáveis dos mesmos para fabricação de medicamento tendo um efeito cicatrizante
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0110430A (pt) Processo para a preparação de um composto, composto, e, uso do mesmo
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
DE60112960D1 (de) Kondensierte pyridoindolderivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure